Nevens F, Van Steenbergen W, Yap S H, Fevery J
Department of Liver and Pancreas Diseases, University Hospital Gasthuisberg, Leuven, Belgium.
Gut. 1996 Jan;38(1):129-34. doi: 10.1136/gut.38.1.129.
Octreotide has been proposed for the treatment of variceal bleeding. The effects on portal pressure, however, have been variable in published studies. As bleeding is more directly related to pressure in the varices, this study investigated the effect on variceal pressure of octreotide and terlipressin, a vasoactive drug with a well established effect. Variceal pressure was measured during four to eight minutes by a continuous non-invasive endoscopic registration method. Thirty patients in whom a stable variceal pressure recording had been obtained during at least one minute, were randomised to receive either 2 mg terlipressin, 50 micrograms octreotide or an identical volume of saline, as a single intravenous injection given over 60 seconds. For the final analysis three patients had to be excluded because of lack of a satisfactory recording. There were no significant clinical differences between the three groups of patients. Placebo administration did not induce significant changes, but a mean decrease in variceal pressure of -27% was noted with terlipressin, starting from two minutes onwards. Variceal pressure changes after injection of octreotide were variable and the mean change in pressure did not reach statistical significance. Seven of 10 patients showed a temporary increase in variceal pressure. In conclusion, terlipressin induces a significant and progressive decrease in variceal pressure but inconsistent variations of variceal pressure changes were seen after octreotide administration. This is probably related to its effect on central venous pressure. This study also shows that continuous variceal pressure recording with the non-invasive endoscopic registration technique detects in an accurate way the effect of vasoactive drugs on variceal pressure, because placebo injection did not produce significant changes.
奥曲肽已被提议用于治疗静脉曲张出血。然而,在已发表的研究中,其对门静脉压力的影响并不一致。由于出血与曲张静脉压力更直接相关,本研究调查了奥曲肽和特利加压素(一种已证实有作用的血管活性药物)对曲张静脉压力的影响。通过连续无创内镜记录方法在4至8分钟内测量曲张静脉压力。30例患者在至少1分钟内获得了稳定的曲张静脉压力记录,他们被随机分为三组,分别接受2毫克特利加压素、50微克奥曲肽或相同体积的生理盐水,均通过静脉在60秒内单次注射。最终分析时,由于记录不令人满意,有3例患者被排除。三组患者之间无显著临床差异。给予安慰剂未引起显著变化,但特利加压素从两分钟起可使曲张静脉压力平均降低27%。注射奥曲肽后曲张静脉压力变化不定,压力的平均变化未达到统计学显著意义。10例患者中有7例出现曲张静脉压力暂时升高。总之,特利加压素可使曲张静脉压力显著且持续降低,但注射奥曲肽后曲张静脉压力变化不一致。这可能与其对中心静脉压的影响有关。本研究还表明,采用无创内镜记录技术连续记录曲张静脉压力能够准确检测血管活性药物对曲张静脉压力的影响,因为注射安慰剂未产生显著变化。